

Updates/Announcements

January 2023

General Updates

NIH launches harm reduction research network to prevent overdose fatalities

To address the overdose crisis in the United States, the National Institutes of Health has established a research network that will test harm reduction strategies in different community settings to inform efforts to help save lives. The harm reduction research network's efforts build on existing harm reduction research, and represent the largest pool of funding from NIH to date to study harm reduction strategies to address overdose deaths.

<https://nida.nih.gov/news-events/news-releases/2022/12/nih-launches-harm-reduction-research-network-to-prevent-overdose-fatalities>

FDA Announces Preliminary Assessment that Certain Naloxone Products Have the Potential to be Safe and Effective for Over-the-Counter Use

The Federal Register notice includes a preliminary assessment that certain naloxone drug products—up to 4 milligrams (mg) nasal spray and up to 2 mg autoinjector for intramuscular (IM) or subcutaneous (SC) use—may be approvable as safe and effective for nonprescription use. This preliminary assessment is intended to facilitate development and approval of nonprescription naloxone products; however, it is not a final determination that certain naloxone drug products are safe and effective for nonprescription use, and it does not mandate an immediately effective switch to nonprescription/over-the-counter (OTC) availability for naloxone.

<https://www.fda.gov/news-events/press-announcements/fda-announces-preliminary-assessment-certain-naloxone-products-have-potential-be-safe-and-effective>

ARS Accepting patients into their IOP Program

I am pleased to announce that ARS of Lancaster is officially accepting patients into our IOP program. Our days of operation are Monday, Wednesday, and Thursday from 11:30a-2:30p. Our location is 2192 Embassy Drive, Lancaster, PA 17603. This program is not part of our MAT (medication assisted treatment) services. MAT patients and non-MAT patients are being accepted at this location. Patients can call 717-394-7160 to schedule an appointment. We also have walk in admissions for both programs Monday-Friday from 5:00a-10:00a. IOP appointments can be scheduled for later assessments.

Alayna P. Hoffman MA CAADC
Executive Director

ARS Lancaster
2192 Embassy Dr
Lancaster, PA 17603

Department of Drug & Alcohol Program (DDAP) Updates

Information Bulletin 03-22 – Negative drug screen

The Department of Drug and Alcohol Programs (DDAP) released [Information Bulletin 03-22: Act 101 of 2022](#), Negative drug test not a basis to deny treatment.

NEW VIRTUAL Training Available

The Department of Drug & Alcohol Programs (DDAP) is pleased to announce an online training module addressing Xylazine and Overdose Response. Please see the attached flyers for more information.

New Online Module: Xylazine: The New Drug Additive

This online training video, presented by Savage Sisters Recovery, will provide information on national and statewide opioid statistics and updates on current drug supply trends, including critical information on Xylazine. Also included in this module is a demonstration of overdose reversal procedures when the presence of Xylazine is suspected. This training will last approximately 30 minutes and is approved for 30 minutes of PCB Continuing Education Credits.



New Online
Module - Xylazine; T